Navigation Links
KemPharm's KP201 to be Featured at PAINWeek 2013
Date:8/28/2013

NORTH LIBERTY, Iowa, Aug. 28, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present a poster on KP201 at PAINWeek 2013, the nation's largest pain conference for frontline clinicians with an interest in pain management.  

The poster, entitled "KP201: A Novel Opioid Pain Therapy with Reduced Abuse Potential and Improved Safety," will be displayed on September 6, 2013 between 6:15 PM and 7:30 PM, PDT and will detail KP201's clinical studies and unique abuse-deterrent properties, which have been shown to significantly limit narcotic exposure upon intranasal administration and intravenous injection.  Additionally, the poster will highlight the potential for KP201 to prevent or reduce opioid-induced constipation (OIC).

Dr. Mickle commented, "Showcasing KP201 at PAINWeek 2013 provides an opportunity for clinicians with an interest in pain management to gain an understanding of the drug's advantages and its potential as a future treatment option for their patients.  We welcome the opportunity to present what we believe is very compelling data on KP201 that highlight not only its ability to treat pain but the added benefit of a reduction in abuse potential and opioid-induced constipation."

About KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com.For KemPharm, Inc:Media / Investor Contacts:Christal Mickle

319-665-2575

info@kempharm.comJason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020

jrando@tiberend.com

jdrumm@tiberend.com  


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
2. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
3. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
4. Millennium HealthCare Inc. Featured in Forbes
5. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
6. Mid-Atlantic Biotech Leaders Featured On BioSpace Map
7. B. Braun Smart Infusion Pump Technology to be Featured in Integrating the Healthcare Enterprise (IHE) Interoperability Demonstration at AAMI 2013
8. Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
9. AVTs Customer Medbox, Inc. Featured in Bloomberg Businessweek
10. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
11. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):